On May 18, 2017, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab). This major regulatory action was granted based on new efficacy data, indicating an expansion of the drug's approved therapeutic applications.
Background
Pembrolizumab, marketed as Keytruda, is a well-established therapeutic agent. This supplemental approval signifies an update to its existing marketing authorization, specifically recognizing additional demonstrated efficacy for the drug in a new context or patient population.
What this means
The FDA's approval of a supplemental efficacy application for Keytruda (pembrolizumab) expands its therapeutic utility. While the specific details of the new indication or patient population are not provided in the source data, this approval confirms that pembrolizumab has met the FDA's standards for demonstrating clinical benefit in an additional area. This allows healthcare providers to consider Keytruda for an expanded range of patients, based on the FDA's assessment of its efficacy profile.
Source
The information regarding this approval was obtained from the U.S. Food and Drug Administration (FDA). The FDA's official overview page for Biologics License Application (BLA) 125514, specifically supplemental application S-17, confirms the approval of Keytruda (pembrolizumab) on May 18, 2017. This record is publicly accessible on accessdata.fda.gov.